| Date Filed | Type | Description |
| 10/06/2023 |
SC 13D/A
| HighCape Capital, L.P. reports a 68% stake in Elutia Inc. |
| 10/05/2023 |
4
| HighCape Capital, LLC (10% Owner) has filed a Form 4 on ELUTIA INC.|
Txns:
| Bought 2,837,128 shares
@ $0
Bought 4,255,693 warrants
@ $1.4275, valued at
$6.1M
|
|
| 10/05/2023 |
4
| HighCape Capital, L.P. (10% Owner) has filed a Form 4 on ELUTIA INC.|
Txns:
| Bought 2,837,128 shares
@ $0
Bought 4,255,693 warrants
@ $1.4275, valued at
$6.1M
|
|
| 10/05/2023 |
3
| Elutia PIPE Investment, LP (10% Owner) has filed a Form 3 on ELUTIA INC. |
| 10/03/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/12/2023 |
4
| HighCape Capital, L.P. (10% Owner) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 37,500 options to buy
@ $2.37, valued at
$88.9k
Granted 25,000 options to buy
@ $2.37, valued at
$59.3k
|
|
| 06/12/2023 |
4
| Makes Brigid (Director) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 25,000 options to buy
@ $2.37, valued at
$59.3k
|
|
| 06/12/2023 |
4
| Colpman David (Director) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 25,000 options to buy
@ $2.37, valued at
$59.3k
|
|
| 06/12/2023 |
4
| Jordan Maybelle (Director) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 25,000 options to buy
@ $2.37, valued at
$59.3k
|
|
| 06/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
4
| Mills C Randal (PRESIDENT AND CEO) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 134,840 restricted stock units
@ $0
Exercised 44,947 restricted stock units
@ $0
Granted 89,894 restricted stock units
@ $0 |
|
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
4
| Birchview Capital, LP (10% Owner) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Bought 100,000 shares
@ $1.491, valued at
$149.1k
Bought 10,000 shares
@ $1.491, valued at
$14.9k
Bought 18,000 shares
@ $1.3539, valued at
$24.4k
Bought 2,000 shares
@ $1.3539, valued at
$2.7k
Bought 10,000 shares
@ $1.587, valued at
$15.9k
|
|
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 4.9% stake in Aziyo Biologics, Inc. |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
4
| Englese Thomas (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Sold 289 shares
@ $4.3, valued at
$1.2k
Exercised 937 restricted stock units
@ $0 |
|
| 03/09/2023 |
4
| Ferguson Matthew (CFO) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Exercised 1,287 restricted stock units
@ $0 |
|
| 02/14/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 10.7% stake in Aziyo Biologics, Inc. |
| 02/14/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 10.7% stake in Aziyo Biologics, Inc. |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Aziyo Biologics Announces Record Annual Net Sales in Preliminary Fourth Quarter and Full Year 2022 Topline Results SILVER SPRING, Md., January 9, 2023 — Aziyo Biologics, Inc. , a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary net sales results for its fourth quarter and full year ended December 31, 2022. Preliminary Fourth Quarter and Full Year 2022 Net Sales Results · Anticipate fourth quarter 2022 net sales of approximately $12.5-$12.7 million, an increase of 15%-17% compared to the same prior year period · Anticipate full year 2022 record net sales of approximately $49.0-$49.2 million, an increase of 3%-4% compared to the prior year and, after excl..." |
|
| 12/30/2022 |
8-K
| Quarterly results |
| 12/28/2022 |
4
| HighCape Partners GP II, LLC (10% Owner) has filed a Form 4 on AZIYO BIOLOGICS, INC.|
Txns:
| Granted 17,533 options to buy
@ $3.8, valued at
$66.6k
|
|
|